乳腺癌患者CD45^-微泡和单个核细胞的特性及其临床意义  

Characteristics and clinical significance of CD45-negative microparticles and monocytes in breast cancer patients

作　　者：王宁方[1] 赵崇山[2] 李娟[3] 胡艳洁[3] 郑芳[3] 王俊峰[3] 黄士昂[3] 

机构地区：[1]中国石油天然气集团公司中心医院血液科,河北廊坊065000 [2]中国石油天然气集团公司中心医院感染科,河北廊坊065000 [3]华中科技大学同济医学院附属协和医院干细胞研究与应用中心,湖北武汉430022

出　　处：《肿瘤》2016年第6期674-682,共9页Tumor

摘　　要：目的 :探讨乳腺癌患者外周血中CD45-微泡(microparticles,MPs)及CD45-单个核细胞(monocytes,MNCs)的临床特性,并分析CD45-MPs与CD45-MNCs水平的相关性。方法 :采用FCM法检测43例乳腺癌患者和10例乳腺纤维瘤患者(作为对照组)外周血中CD45-MPs及CD45-MNCs的水平,进一步检测CD45-MPs和CD45-MNCs中CD44+、CD24+和CD44+CD24-细胞的所占百分比。最后分析各种CD45-MPs和CD45-MNCs与乳腺癌患者临床病理特征[包括组织学分级以及人类表皮生长因子受体2(human epidermal growth factor receptor-2,HER-2)、雌激素受体(estrogen receptor,ER)和孕激素受体(progesterone receptor,PR)表达等]的关系,以及CD45-MNCs与CD45-MPs之间的相关性。结果 :乳腺癌组的CD45-MPs中,CD44+MPs和CD44+CD24-MPs所占百分比均明显高于对照组(P值均<0.01),而CD24+MPs与CD44+MPs的比值(CD24/CD44)明显低于对照组(P<0.01)。乳腺癌患者中CD24+MPs所占百分比在原位癌、浸润性导管癌、黏液癌、浸润性小叶癌、髓样癌和乳头状癌中依次升高(P<0.01)。乳腺癌患者中,HER-2++组CD44+CD24-MPs所占百分比明显低于HER-2+组(P<0.05),CD24/CD44比值随着组织学分级升高也呈升高趋势(P<0.05),且ER-和PR-组中CD24/CD44比值明显高于ER+和PR+组(P<0.01,P<0.05)。乳腺癌患者的CD45-MNCs中,CD44+MNCs和CD44+CD24-MNCs所占百分比均明显低于对照组(P值均<0.05);而CD24+MNCs所占百分比则明显高于对照组(P<0.05),且随着组织学分级升高而逐渐升高(P<0.05)。乳腺癌患者的CD44+MNCs、CD44+CD24-MNCs与CD44+MPs和CD44+CD24-MPs之间均存在明显的正相关关系(P值均<0.05)。结论 :CD45-MPs和CD45-MNCs在乳腺癌发生及发展过程中可能发挥一定作用。Objective： To explore the clinical characteristics of CD45-negative microparticles （CD45-MPs） and monocytes （CD45-MNCs） in peripheral blood from the patients with breast cancer, and to analyze the correlation between CD45-MPs and CD45-MNCs. Methods： The levels of CD45-MPs and CD45-MNCs in peripheral blood from 43 patients with breast cancer and 10 patients with mammary gland fibroma （as the control） were detected by flow cytometry. Furthermore, the percentages of CD44＋, CD24＋, and CD44＋CD24- cells in CD45-MPs and CD45-MNCs were detected by flow cytometry. At last, the correlation of CD45- MPs and CD45-MNCs with the clinicopathological features including histologic grade and the expressions of human epidermal growth factor receptor 2 （HER-2）, estrogen receptor （ER） and progesterone receptor （PR） in breast cancer patients, as well as the correlation between CD45-MPs and CD45-MNCs were analyzed. Results： The percentages of CD44＋MPs and CD44＋CD24-MPs in CD45-MPs of breast cancer patients were significantly higher than those of the control group （both P 〈 0.01）. However, the ratio of CD24＋MPs to CD44＋MPs （CD24/CD44） in CD45-MPs of breast cancer patients was significantly lower than that in the control group （P 〈 0.01）. The percentages of CD24＋MPs in carcinoma in situ, infiltrating ductal carcinoma, mucinous carcinoma, infiltrating Iobular carcinoma, medullary carcinoma and papillary carcinoma were gradually increased （P 〈 0.01）. The percentage of CD44＋CD24-MPs in HER-2＋＋ group of breast cancer patients was significantly lower than that in HER-2＋ group （P 〈 0.05）. The ratio of CD24/CD44 in CD45- MPs of breast cancer patients was elevated with the increase of histologic grade （P 〈 0.05）, and the ratio of CD24/CD44 in ER- and PR- groups was higher than that in ER＋ and PR＋ groups （P 〈 0.01, P 〈 0.05）. The percentages of CD44＋MNCs and CD44＋CD24-MNCs in CD45- MNCs of breast cancer patients were statistically lower than th

关 键 词：乳腺肿瘤 细胞源性微粒 单核细胞 抗原 CD45 流式细胞术 

分 类 号：R737.9[医药卫生—肿瘤]